222 related articles for article (PubMed ID: 20536296)
1. Pharmacogenetics of toxic epidermal necrolysis.
Lee MT; Hung SI; Wei CY; Chen YT
Expert Opin Pharmacother; 2010 Sep; 11(13):2153-62. PubMed ID: 20536296
[TBL] [Abstract][Full Text] [Related]
2. Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population.
Tassaneeyakul W; Jantararoungtong T; Chen P; Lin PY; Tiamkao S; Khunarkornsiri U; Chucherd P; Konyoung P; Vannaprasaht S; Choonhakarn C; Pisuttimarn P; Sangviroon A; Tassaneeyakul W
Pharmacogenet Genomics; 2009 Sep; 19(9):704-9. PubMed ID: 19696695
[TBL] [Abstract][Full Text] [Related]
3. HLA-B*1502 strongly predicts carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Thai patients with neuropathic pain.
Kulkantrakorn K; Tassaneeyakul W; Tiamkao S; Jantararoungtong T; Prabmechai N; Vannaprasaht S; Chumworathayi P; Chen P; Sritipsukho P
Pain Pract; 2012 Mar; 12(3):202-8. PubMed ID: 21676164
[TBL] [Abstract][Full Text] [Related]
4. Genetic markers and danger signals in stevens-johnson syndrome and toxic epidermal necrolysis.
Chung WH; Hung SI
Allergol Int; 2010 Dec; 59(4):325-32. PubMed ID: 20962567
[TBL] [Abstract][Full Text] [Related]
5. A study of HLA class I and class II 4-digit allele level in Stevens-Johnson syndrome and toxic epidermal necrolysis.
Cristallo AF; Schroeder J; Citterio A; Santori G; Ferrioli GM; Rossi U; Bertani G; Cassano S; Gottardi P; Ceschini N; Barocci F; Ribizzi G; Cutrupi V; Cairoli R; Rapisarda V; Pastorello EA; Barocci S
Int J Immunogenet; 2011 Aug; 38(4):303-9. PubMed ID: 21545408
[TBL] [Abstract][Full Text] [Related]
6. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs.
Lonjou C; Borot N; Sekula P; Ledger N; Thomas L; Halevy S; Naldi L; Bouwes-Bavinck JN; Sidoroff A; de Toma C; Schumacher M; Roujeau JC; Hovnanian A; Mockenhaupt M;
Pharmacogenet Genomics; 2008 Feb; 18(2):99-107. PubMed ID: 18192896
[TBL] [Abstract][Full Text] [Related]
7. Recent advances in the genetics and immunology of Stevens-Johnson syndrome and toxic epidermal necrosis.
Chung WH; Hung SI
J Dermatol Sci; 2012 Jun; 66(3):190-6. PubMed ID: 22541332
[TBL] [Abstract][Full Text] [Related]
8. T-cell receptor and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: understanding a hypersensitivity reaction.
Ko TM; Chen YT
Expert Rev Clin Immunol; 2012 Jul; 8(5):467-77. PubMed ID: 22882221
[TBL] [Abstract][Full Text] [Related]
9. Human leukocyte antigens and drug hypersensitivity.
Chung WH; Hung SI; Chen YT
Curr Opin Allergy Clin Immunol; 2007 Aug; 7(4):317-23. PubMed ID: 17620823
[TBL] [Abstract][Full Text] [Related]
10. Genetic predisposition of life-threatening antiepileptic-induced skin reactions.
Chung WH; Hung SI; Chen YT
Expert Opin Drug Saf; 2010 Jan; 9(1):15-21. PubMed ID: 20001755
[TBL] [Abstract][Full Text] [Related]
11. Shared and restricted T-cell receptor use is crucial for carbamazepine-induced Stevens-Johnson syndrome.
Ko TM; Chung WH; Wei CY; Shih HY; Chen JK; Lin CH; Chen YT; Hung SI
J Allergy Clin Immunol; 2011 Dec; 128(6):1266-1276.e11. PubMed ID: 21924464
[TBL] [Abstract][Full Text] [Related]
12. [Stevens-Johnson syndrome and toxic epidermal necrolysis--updates and innovations].
Halevy S
Harefuah; 2010 Mar; 149(3):186-90, 193. PubMed ID: 20684173
[TBL] [Abstract][Full Text] [Related]
13. Stevens-Johnson syndrome, drug-induced hypersensitivity syndrome and toxic epidermal necrolysis caused by allopurinol in patients with a common HLA allele: what causes the diversity?
Dainichi T; Uchi H; Moroi Y; Furue M
Dermatology; 2007; 215(1):86-8. PubMed ID: 17587850
[No Abstract] [Full Text] [Related]
14. Stevens-Johnson syndrome and toxic epidermal necrolysis: what do we know?
Tartarone A; Lerose R
Ther Drug Monit; 2010 Dec; 32(6):669-72. PubMed ID: 20844465
[TBL] [Abstract][Full Text] [Related]
15. Association between carbamazepine-induced cutaneous adverse drug reactions and the HLA-B*1502 allele among patients in central China.
Wu XT; Hu FY; An DM; Yan B; Jiang X; Kwan P; Stefan H; Zhou D
Epilepsy Behav; 2010 Nov; 19(3):405-8. PubMed ID: 20833111
[TBL] [Abstract][Full Text] [Related]
16. Spontaneous adverse event reports of Stevens-Johnson syndrome/toxic epidermal necrolysis: detecting associations with medications.
Papay J; Yuen N; Powell G; Mockenhaupt M; Bogenrieder T
Pharmacoepidemiol Drug Saf; 2012 Mar; 21(3):289-96. PubMed ID: 22139991
[TBL] [Abstract][Full Text] [Related]
17. Association of Fas Ligand gene polymorphism with Stevens-Johnson syndrome.
Ueta M; Sotozono C; Inatomi T; Kojima K; Hamuro J; Kinoshita S
Br J Ophthalmol; 2008 Jul; 92(7):989-91. PubMed ID: 18577653
[TBL] [Abstract][Full Text] [Related]
18. Medications as risk factors of Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis.
Levi N; Bastuji-Garin S; Mockenhaupt M; Roujeau JC; Flahault A; Kelly JP; Martin E; Kaufman DW; Maison P
Pediatrics; 2009 Feb; 123(2):e297-304. PubMed ID: 19153164
[TBL] [Abstract][Full Text] [Related]
19. Phenotype standardization for immune-mediated drug-induced skin injury.
Pirmohamed M; Friedmann PS; Molokhia M; Loke YK; Smith C; Phillips E; La Grenade L; Carleton B; Papaluca-Amati M; Demoly P; Shear NH
Clin Pharmacol Ther; 2011 Jun; 89(6):896-901. PubMed ID: 21562486
[TBL] [Abstract][Full Text] [Related]
20. Genetic association of IFN-γ +874T/A polymorphism in Mexican patients with drug-induced Stevens-Johnson syndrome/toxic epidermal necrolysis.
Charli-Joseph Y; Lima G; Ramos-Bello D; Aguilar D; Orozco-Topete R; Llorente L
Arch Dermatol Res; 2013 May; 305(4):353-7. PubMed ID: 23224615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
